Ozempic vs Mounjaro — GLP-1 vs dual GIP/GLP-1 agonist. Trial weight-loss comparison (~15% vs ~20%), indications, and Nepal availability.
Short answer: Ozempic (semaglutide) is a GLP-1 agonist; Mounjaro (tirzepatide) is a dual GIP+GLP-1 agonist. Head-to-head trials show tirzepatide produces more weight loss (~20% vs ~15%) and greater HbA1c reduction. Both are weekly injections; Mounjaro's Nepal availability is more limited.
Tirzepatide outperforms on weight and glucose in trials — dual agonism is a real mechanistic advantage. But 'better on average' isn't 'better for everyone' — availability, cost, tolerability, and your specific clinical picture determine which fits.
Ozempic program | Nepal treatment guide | FAQs | What is Ozempic? | Dosage | Who should avoid | Drug interactions | Monitoring | Results | Vs Wegovy vs Mounjaro | Diet & exercise | Price in Nepal | Stree Clinic | Lead Doctor | Weight loss | Diabetes care | Side effects | Success stories | Editorial policy | How to get Ozempic | Results timeline | Meal plan | Injection guide | Storage & cold chain | Myths vs facts | नेपालीमा | Conditions treated | Clinical trials | BMI eligibility | BMI calculator | Without diabetes | Fake semaglutide warning | Ozempic & alcohol | Vs Saxenda | PCOS | Fatty liver | Kidney disease | Prediabetes | Heart health | Alternatives | Ozempic face | Hair loss | Stopping Ozempic | For men | For women | Not losing weight | Semaglutide in Nepal | GLP-1 treatment | Find a doctor | Availability | Medical weight loss | Obesity treatment | Diabetes doctor | Eligibility | Insulin resistance | Wegovy in Nepal | Mounjaro in Nepal | Rybelsus in Nepal | Areas served | Find a specialist | Weight loss medication | Book consultation | Ozempic vs keto | Vs low-carb | Vs calorie deficit | Vs exercise | Vs diet & exercise | Vs intermittent fasting | Vs fasting | Vs natural weight loss | Vs lifestyle changes | Vs medical weight mgmt | Vs dietitian-guided | Vs bariatric surgery | Request assessment
On weight loss and HbA1c, trial data says yes (~20% vs ~15%, ~2% vs ~1.5%). But availability, cost, and individual tolerance decide what's right for you.
Less established than semaglutide — confirm availability at a specialist consultation rather than assuming retail stock.
SURPASS-2 head-to-head (NEJM 2021); SURMOUNT trials; FDA labels.
Browse all pages